Clinical trials
Pulmonary Arterial Hypertension clinical trials
Below are recruiting pulmonary arterial hypertension clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02691689Recruiting
Genetics study in families with congenital heart defects and PAH
This study looks at genes that may contribute to pulmonary arterial hypertension (PAH) in people born with certain heart “shunts” (holes between heart chambers). If you have (or your family has) ASD or VSD and PAH confirmed by a heart pressure test, you may be invited to share genetic and health information to help researchers understand risk and better target future care.
LeuvenAges 18 years+ - NCT01730092Recruiting
Study of blood and imaging biomarkers in pulmonary artery hypertension
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
Bethesda, MarylandAges 18–100 - NCT01725763Enrolling by invitation
MRI without contrast to help diagnose pulmonary hypertension
This study uses an MRI scan that does not use contrast dye to better diagnose and sort out pulmonary hypertension (high blood pressure in the lungs). It may help doctors classify your condition more accurately, especially around the time you’re scheduled for a right-heart catheterization.
Graz, StyriaAges 18 years+ - NCT01884051Recruiting
Study of blood and skin changes in pulmonary hypertension
This study looks at how hormones, metabolism, and body signals relate to pulmonary arterial hypertension. You may be eligible if you (or a family member) have idiopathic, inherited, or related pulmonary arterial hypertension, and you can do required blood and other testing.
Nashville, TennesseeAges Up to 90 years - NCT01571700Enrolling by invitation
Study breathing-heart timing differences in pulmonary hypertension
This study looks at timing mismatches (“dysynchrony”) in the heart and lungs in people with pulmonary hypertension. It may help researchers understand what causes symptoms and how the timing affects heart function.
Stanford, CaliforniaAges 5 years+ - NCT07850908Enrolling by invitation
Ventilation method for newborns with persistent pulmonary hypertension
This study tests a specific type of breathing machine (ventilator) that adjusts air pressure to help newborns with persistent pulmonary hypertension breathe better. It aims to see if this method improves oxygen levels and outcomes for babies needing mechanical ventilation in their first week of life.
Tanta, Gharbia GovernorateAges 1 day–2 months - NCT07666841Recruiting
Home-based pulmonary rehab for chronic lung disease
This study tests whether a home-based pulmonary rehabilitation program using a smartphone or computer works as well as in-person rehab for people with chronic lung diseases like COPD or lung scarring. It aims to help you breathe better and feel stronger from home.
AshkelonAges 18 years+ - NCT06495970Recruiting
Pulmonary artery denervation for heart failure with lung hypertension
This trial tests a procedure called pulmonary artery denervation (PADN) for people with heart failure and a certain type of high blood pressure in the lungs (pulmonary hypertension Group 2). The goal is to see if using a special device called the Gradient Denervation System can help control the high pressures and improve your symptoms.
BadalonaAges 22–85 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Phoenix, ArizonaAges birth–20 years - NCT06770023RecruitingPhase 1
Bridge to lung transplant with ECMO for right heart failure
This study tests a special heart-lung support machine (ECMO) for people waiting for a lung transplant whose heart is failing due to high blood pressure in the lungs. The machine helps rest the heart and lungs until transplant surgery.
Jacksonville, FloridaAges 18–80 - NCT06052072Enrolling by invitation
Heart failure trial testing nerve treatment for lung pressure
This trial tests a new treatment that uses a device to calm overactive nerves in the lung's blood vessels. It is for heart failure patients who also have high blood pressure in their lungs, to see if it can help them breathe easier and feel better.
Chicago, IllinoisAges 22–85 - NCT06331208Recruiting
Mechanisms of Lung Blood Vessel Problems in Heart Failure
This study looks at how heart failure affects blood vessels in the lungs. If you have heart failure with reduced pumping ability and need a heart catheterization, you may be able to join.
PragueAges 18 years+ - NCT04898114RecruitingPhase 1/Phase 2
Inhaled magnesium and sildenafil for newborn lung blood pressure
This study tests whether breathing in magnesium sulfate and giving sildenafil can improve breathing and lung blood vessel pressure in newborns with persistent pulmonary hypertension. It may help newborns who are having trouble oxygenating despite being on a ventilator.
SohagAges 6 hours–3 days - NCT07311135Recruiting
Smartwatch Oxygen Accuracy in Pulmonary Hypertension
This study tests how well a smartwatch measures oxygen levels in people with pulmonary hypertension during a 6-minute walk. It could help find a simpler way to check oxygen at home.
GlasgowAges 18 years+ - NCT04078243Recruiting
Trial setup and testing in adults with pulmonary hypertension
This study tests new “trial tools” and designs for running early research in people with pulmonary hypertension. If you qualify, you may be asked to do extra trial-related procedures to help researchers test the process safely and smoothly.
Sheffield, South YorkshireAges 18 years+ - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70 - NCT06476470Recruiting
Taiwan ILD registry for understanding lung disease
This registry is gathering information from people with different types of interstitial lung disease (ILD) across Taiwan. It aims to better understand the disease and improve future care.
TaichungAges 18 years+ - NCT06605794Recruiting
FreeFlow heart shunt for severe idiopathic pulmonary hypertension
This trial tests a new device called FreeFlow, which creates a small opening in the wall between the top chambers of the heart to relieve pressure. It is for people with severe idiopathic pulmonary hypertension who still have serious symptoms despite standard medications.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07623525RecruitingPhase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
Camperdown, New South WalesAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT06753981Recruiting
Triple drug therapy for new PAH patients
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Jinan, ShandongAges 18–80 - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+ - NCT06865118Recruiting
Home management of heart issues in scleroderma
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
OsloAges 18 years+ - NCT07245680RecruitingPhase 3
Testing two pills vs one for pulmonary hypertension with heart or metabolism issues
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Le Kremlin-BicêtreAges 18 years+
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary arterial hypertension?
- Yes. Clin2 currently lists 175 recruiting pulmonary arterial hypertension studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary arterial hypertension trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary arterial hypertension trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
- Heritable Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Artery Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.